Mustang Bio

Mustang Bio Dividend Coverage

Dividend Coverage Ratio of Mustang Bio (MBIO) as of Oct 18, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Mustang Bio is 2026 - . Dividend Coverage Ratio of Mustang Bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mustang Bio Stock analysis

What does Mustang Bio do? Mustang Bio Inc., based in New York City, is a clinical-stage biopharmaceutical company operating in the Health Care sector. It specializes in developing proprietary CAR T immunotherapies and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. The company, listed on 22 August 2017, focuses on translating cell and gene therapy breakthroughs into potential cures, with pipeline programs including MB-107 for X-linked severe combined immunodeficiency and MB-102 for acute myeloid leukemia. Mustang Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mustang Bio stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Mustang Bio since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Mustang Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Mustang Bio

All Key Metrics — Mustang Bio